The stock of DexCom, Inc. (NASDAQ:DXCM) is a huge mover today! About 973,381 shares traded hands. DexCom, Inc. (NASDAQ:DXCM) has declined 14.77% since April 4, 2016 and is downtrending. It has underperformed by 15.86% the S&P500.
The move comes after 7 months positive chart setup for the $5.20 billion company. It was reported on Nov, 4 by Barchart.com. We have $98.50 PT which if reached, will make NASDAQ:DXCM worth $3.07 billion more.
DexCom, Inc. (NASDAQ:DXCM) Ratings Coverage
Out of 12 analysts covering Dexcom (NASDAQ:DXCM), 11 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 92% are positive. Dexcom has been the topic of 18 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The company was maintained on Friday, August 7 by Piper Jaffray. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, November 2 report. Robert W. Baird downgraded the stock to “Neutral” rating in Monday, February 8 report. The rating was maintained by Deutsche Bank on Friday, July 15 with “Buy”. The firm has “Overweight” rating given on Wednesday, February 24 by JP Morgan. The firm has “Buy” rating given on Friday, September 16 by Desjardins Securities. The rating was maintained by Benchmark with “Buy” on Wednesday, February 24. As per Monday, October 31, the company rating was upgraded by BTIG Research. The stock has “Buy” rating given by Sterne Agee CRT on Thursday, October 15. JP Morgan maintained the stock with “Overweight” rating in Thursday, September 17 report.
According to Zacks Investment Research, “Dexcom Inc. is developing continuous glucose monitoring systems for people with diabetes.”
Insitutional Activity: The institutional sentiment increased to 1.35 in Q2 2016. Its up 0.40, from 0.95 in 2016Q1. The ratio improved, as 30 funds sold all DexCom, Inc. shares owned while 77 reduced positions. 46 funds bought stakes while 98 increased positions. They now own 82.43 million shares or 5.55% more from 78.09 million shares in 2016Q1.
Marsico Mgmt Ltd has 0.15% invested in the company for 55,398 shares. Wfg Advsrs L P holds 1 shares or 0% of its portfolio. Eqis Capital Mngmt, a California-based fund reported 7,246 shares. Raymond James Fincl Advsrs owns 17,335 shares or 0.01% of their US portfolio. Jpmorgan Chase & Com reported 104,923 shares or 0% of all its holdings. Schwab Charles Investment Mgmt has 197,964 shares for 0.02% of their US portfolio. Ameriprise Inc last reported 3.97 million shares in the company. Savings Bank Of America Corp De reported 678,889 shares or 0.01% of all its holdings. Moreover, Cibc Asset Mgmt has 0% invested in DexCom, Inc. (NASDAQ:DXCM) for 2,656 shares. Principal Gp Inc holds 0.01% of its portfolio in DexCom, Inc. (NASDAQ:DXCM) for 82,602 shares. Lord Abbett & Limited Liability Company accumulated 0.05% or 213,188 shares. Massachusetts Fincl Svcs Company Ma accumulated 392,957 shares or 0.02% of the stock. Moreover, Blackrock Fund has 0.02% invested in DexCom, Inc. (NASDAQ:DXCM) for 1.08M shares. Alliancebernstein Limited Partnership holds 0.12% or 1.71 million shares in its portfolio. Carlson Cap L P holds 104,550 shares or 0.1% of its portfolio.
Insider Transactions: Since May 9, 2016, the stock had 0 buys, and 67 insider sales for $61.41 million net activity. 1,674 shares were sold by DOUBLEDAY RICHARD, worth $106,446 on Monday, May 23. 5,000 DexCom, Inc. (NASDAQ:DXCM) shares with value of $464,366 were sold by Balo Andrew K. 3,560 DexCom, Inc. (NASDAQ:DXCM) shares with value of $333,392 were sold by LISTER JOHN. 3,471 shares were sold by ROPER JESS, worth $239,500. VALDES JORGE A sold $928,579 worth of stock or 11,000 shares. $642,527 worth of DexCom, Inc. (NASDAQ:DXCM) was sold by SAYER KEVIN R on Wednesday, September 14. 3,000 shares with value of $182,175 were sold by KAHN BARBARA on Thursday, May 12.
More recent DexCom, Inc. (NASDAQ:DXCM) news were published by: Fool.com which released: “Here’s Why DexCom, Inc. Is Plunging Today” on November 02, 2016. Also Businesswire.com published the news titled: “DexCom, Inc. Reports Third Quarter 2016 Financial Results” on November 01, 2016. Nasdaq.com‘s news article titled: “Commit To Buy DexCom At $55, Earn 11.8% Annualized Using Options” with publication date: November 04, 2016 was also an interesting one.
DXCM Company Profile
Dexcom, Inc. (Dexcom), incorporated on May 13, 1999, is a medical device company. The Firm is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. The Company’s products consist of SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. The Firm had received Conformite Europeene Marking (CE Mark) approval for its fourth generation continuous glucose monitoring system, the DexCom G4 system, enabling commercialization of the DexCom G4 system in the European Union, Australia, New Zealand and the countries in Asia and Latin America.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.